Safety and effectiveness of LORLAtinib as a FIRST-line treatment in an ALK-positive Advanced Non-Small Cell Lung Cancer Spanish population. (LORLA-FIRST).

04/06/2025
04/06/2025
EU PAS number:
EUPAS1000000406
Study
Planned
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

B7461054_Non-Interventional Study Protocol_V1.0_10APR2025_Redacted.pdf

English (15.13 MB - PDF) View document
Study results
Study report
Other information